

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| <p style="text-align: center;">Licensee</p> <p>1. Thomas Health System</p> <p>2. 4605 MacCorkle Avenue, SW South Charleston, WV 25309-1311</p> | <p>In accordance with letter dated May 26, 2017.</p> <p>3. License number: 47-17746-01 is amended in its entirety to read as follows:</p> | <p>4. Expiration Date: January 31, 2024</p> <p>5. Docket No.: 030-13267 Reference No.: 47-17745-01</p> |
|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|

| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
|-------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| A. Any byproduct material permitted by 10 CFR 35.100 | A. Any | A. As Needed | A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. |
| B. Any byproduct material permitted by 10 CFR 35.200 | B. Any | B. As Needed | B. For use in imaging and localization studies permitted by 10 CFR 35.200. |
| C. Any byproduct material permitted by 10 CFR 35.300 | C. Any | C. 1 curie total | C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75. |

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at:
- A. Thomas Memorial Hospital, 4605 MacCorkle Avenue, SW, South Charleston, West Virginia.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-17746-01

Docket or Reference Number
030-13267 47-17745-01

Amendment No. 53

B. Saint Francis Hospital, 333 Laidley Street, Charleston, West Virginia.

11. The Radiation Safety Officer (RSO) for this license is Barry L. Davis.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Material and Use

David Abramowitz, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Nicholas M. Cassis, Jr., M.D.

10 CFR 35.100, 10 CFR 35.200, Oral administration of sodium iodide iodine-131

Mohammed Babar Yousaf, M.D.

10 CFR 35.200

James Baek, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Ahmed Sakkal, M.D.

10 CFR 35.200

Jane MaLoof, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Mary Elizabeth Faw, M.D.

10 CFR 35.300

Adam Thomas Krompecher, M.D.

10 CFR 35.100, 10 CFR 35.200, Oral administration of sodium iodide iodine-131

Ziad Kahwash, M.D.

Oral administration of sodium iodide iodine-131

Daniel Adam Rodgers, M.D.

10 CFR 35.100, 10 CFR 35.200, Oral administration of sodium iodide iodine-131

Mohammed Y. Haffar, M.D.

10 CFR 35.200

Bassam Moushmouth, M. D.

10 CFR 35.200

Jashvantlal Thakkar, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
47-17746-01

Amendment No. 53

Docket or Reference Number
030-13267 47-17745-01

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated November 3, 2013 [ML13330B614]
 - B. Letter dated January 3, 2014 [ML14021A024]
 - C. Application dated February 21, 2014 [ML14085A454]
 - D. Letter dated March 12, 2014 [ML14093A195]
 - E. Letter dated February 24, 2015 [ML15086A147]
 - F. Letter dated May 8, 2015 [ML15149A377]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: July 12, 2017By: *Lester Tripp*
Lester Tripp
Region 1